Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer
肌少症和高中性粒细胞/淋巴细胞比值(NLR)与非小细胞肺癌患者二线帕博利珠单抗治疗后出现超进展性疾病相关。
期刊:Clinical and Experimental Immunology
影响因子:3.8
doi:10.1111/cei.13505
Petrova, M P; Donev, I S; Radanova, M A; Eneva, M I; Dimitrova, E G; Valchev, G N; Minchev, V T; Taushanova, M S; Boneva, M V; Karanikolova, T S; Gencheva, R B; Zhbantov, G A; Ivanova, A I; Timcheva, C V; P Pavlov, B; Megdanova, V G; Robev, B S; Conev, N V